Clinical development of cancer therapeutics that target metabolism.

Glucose and glutamine metabolism in cancer cells are markedly elevated relative to non-transformed normal cells. This metabolic reprogramming enables the production of adenosine triphosphate and the anabolic precursors needed for survival, growth and motility. The recent observations that mutant oncogenic proteins and the loss of tumor suppressors activate key metabolic enzymes suggest that selective inhibition of these enzymes may yield effective cancer therapeutics with acceptable toxicities. In support of this concept, pre-clinical studies of small molecule antagonists of several metabolic enzymes in tumor-bearing mice have demonstrated reasonable therapeutic indices. We will review the rationale for targeting metabolic enzymes as a strategy to treat cancer and will detail the results of several recent clinical trials of metabolic inhibitors in advanced cancer patients.

[1]  T. Mikkelsen,et al.  NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Webster K. Cavenee,et al.  Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance , 2015, Proceedings of the National Academy of Sciences.

[3]  R. Lo,et al.  Vemurafenib resistance reprograms melanoma cells towards glutamine dependence , 2015, Journal of Translational Medicine.

[4]  S. Powell,et al.  Phase II study of dichloroacetate (DCA) in combination with chemoradiation (CRT) for unresected, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). , 2015 .

[5]  S. Botton.  O11.3Targeting isocitrate dehydrogenase (IDH)1 and IDH2 mutations Clinical results in advanced hematologic malignancies , 2015 .

[6]  B. Telfer,et al.  Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport , 2014, Molecular Cancer Therapeutics.

[7]  F. Bianchini,et al.  Extracellular acidity, a “reappreciated” trait of tumor environment driving malignancy: perspectives in diagnosis and therapy , 2014, Cancer and Metastasis Reviews.

[8]  A. Yalçin,et al.  6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27 , 2014, Cell Death and Disease.

[9]  J. Shuster,et al.  Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors , 2014, Investigational New Drugs.

[10]  Jennifer B Dennison,et al.  Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.

[11]  J. Chesney,et al.  Estradiol Stimulates Glucose Metabolism via 6-Phosphofructo-2-kinase (PFKFB3)* , 2014, The Journal of Biological Chemistry.

[12]  A. Eisbruch,et al.  Phase 2 Trial of AT-101 in Combination With Docetaxel for Recurrent, Locally Advanced, or Metastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC) , 2014 .

[13]  Ana Kilić,et al.  Regulation of metabolism by cGMP. , 2013, Pharmacology & therapeutics.

[14]  John L Cleveland,et al.  Targeting lactate metabolism for cancer therapeutics. , 2013, Journal of Clinical Investigation.

[15]  T. Mak,et al.  Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. , 2013, Cancer discovery.

[16]  J. Trent,et al.  Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer , 2013, Molecular Cancer Therapeutics.

[17]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[18]  J. Schlesselman,et al.  A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors , 2013, Cancer Chemotherapy and Pharmacology.

[19]  A. Lane,et al.  Control of Glutamine Metabolism By the Tumor Suppressor Rb , 2013, Oncogene.

[20]  J. Chesney,et al.  Molecular Pathways: Regulation of Metabolism by RB , 2012, Clinical Cancer Research.

[21]  A. Retter.  Translational assessment of the efficacy of CPI-613 against pancreatic cancer in animal models versus patients with stage IV disease. , 2012 .

[22]  K. Flaherty,et al.  Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Takashi Tsukamoto,et al.  Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. , 2012, Cell metabolism.

[24]  J. Pouysségur,et al.  CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors , 2011, Proceedings of the National Academy of Sciences.

[25]  P. Bingham,et al.  Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo , 2011, Journal of Molecular Medicine.

[26]  N. Martin,et al.  Bicarbonate and dichloroacetate: Evaluating pH altering therapies in a mouse model for metastatic breast cancer , 2011, BMC Cancer.

[27]  A. Tan,et al.  Phase I study of at-101 (R-(-)-gossypol) in combination with paclitaxel (P) and carboplatin (C) in solid tumors including castrate-resistant prostate cancer (CRPC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Kevin Bray,et al.  Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies , 2010, The Prostate.

[29]  C. Dang,et al.  Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. , 2010, Cancer cell.

[30]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[31]  J. Mackey,et al.  Metabolic Modulation of Glioblastoma with Dichloroacetate , 2010, Science Translational Medicine.

[32]  W. Linehan,et al.  LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer , 2009, Molecular Cancer Therapeutics.

[33]  Jennifer E. Van Eyk,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2016 .

[34]  F. Castell,et al.  Quantitative techniques in 18FDG PET scanning in oncology , 2008, British Journal of Cancer.

[35]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[36]  G. Semenza,et al.  Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 , 2007, Molecular and Cellular Biology.

[37]  John Calvin Reed,et al.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.

[38]  B. Landau,et al.  Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. , 1958, Journal of the National Cancer Institute.

[39]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[40]  G. J. Strijkersb,et al.  Correction for “ CD 147 subunit of lactate / H + symporters MCT 1 and hypoxia-inducible MCT 4 is critical for energetics and growth of glycolytic tumors , 2012 .

[41]  Tsung-Cheng Chang,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[42]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.